A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes

Journal of Geriatric Oncology

Volumn 4, Issue 2, 2013, Pages 157-165

  Davidoff, Amy J ^a   Zuckerman, Ilene H ^b   Pandya, Naimish ^c   Hendrick, Franklin ^b   Ke, Xuehua ^b   Hurria, Arti ^d   Lichtman, Stuart M ^e   Hussain, Arif ^c   P Weiner, Jonathan ^f   Edelman, Martin J ^c  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer; Functional status; Health status; Medicare; Observational study; Treatment selection bias

Indexed keywords

AGED; ALGORITHM; ARTICLE; CALIBRATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CONSTRUCT VALIDITY; CONTROLLED STUDY; COVARIANCE; DISABILITY; DISABILITY STATUS; FEMALE; FUNCTIONAL STATUS; HEALTH INSURANCE; HEALTH STATUS; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RATING SCALE; SELF REPORT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ALGORITHMS; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MULTIVARIATE ANALYSIS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84875632158     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.12.005     Document Type: Article

References (33)

1. Dreyer N.A., Tunis S.R., Berger M., Ollendorf D., Mattox P., Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 2010, 29:1818-1825.
2. Fleurence R.L., Naci H., Jansen J.P. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood) 2010, 29:1826-1833.
3. Potosky A.L.M., Riley G.F.M., Lubitz J.D., Mentnech R.M., Kessler L.G. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993, 31:732-748.
4. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40:IV-3-IV-18.
5. Klabunde C.N., Warren J.L., Legler J.M. Assessing comorbidity using claims data: an overview. Med Care 2002, 40:IV-26-IV-35.
6. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
7. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407-1427.
8. Baldwin L.M., Klabunde C.N., Green P., Barlow W., Wright G. In search of the perfect comorbidity measure for use with administrative claims data: does it exist?. Med Care 2006, 44:745-753.
9. Giordano S.H., Kuo Y., Duan Z., Hortobagyi G.N., Freeman J., Goodwin J.S. Limits of observational data in determining outcomes from cancer therapy. Cancer 2008, 112:2456-2466.
10. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of chemotherapeutic agents 1949, 169. Columbia University Press, New York. C.M. MacLeod (Ed.).
11. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-656.
12. National Comprehensive Cancer Network Clinical practice guidelines in oncology http://www.nccn.org.
13. Deppermann K.M. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 2001, 33:S115-S120.
14. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005, 23:190-196.
15. Salloum R.G., Smith T.J., Jensen G.A., Lafata J.E. Using claims-based measures to predict performance status score in patients with lung cancer. Cancer 2011, 117:1038-1048.
16. Adler G.S. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev 1994, 15:153-163.
17. Centers for Medicare and Medicaid Services Berenson-Eggers type of service (BETOS) https://www.cms.gov/HCPCSReleaseCodeSets/20_BETOS.asp.
18. Wang P.S., Walker A., Tsuang M., Orav E.J., Levin R., Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol 2000, 53:571-578.
19. Shtatland E.S., Barton M.B., Cain E. The perils of stepwise logistic regression and how to escape them using information criteria and the output delivery system. SUGI '26 Proceeding, Paper 258-28 2001, SAS Institute, Inc., Cary, NC.
20. Shtatland E.S., Kleinman K., Cain E. A new strategy of model building in proc logistic with automatic variable selection, validation, shrinkage, and model averaging. SUGI '29 Proceeding, Paper 191-29 2002, SAS Institute, Inc., Cary, NC.
21. Spiegelhalter D.J., Best N.G., Carlin B.P., van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc B 2002, 64:583-639.
22. Lipsitz S.R., Ritzmaurice G.M., Molenberghs G. Goodness-of-fit tests for ordinal response regression models. J R Stat Soc Ser C Appl Stat 1996, 45:175-190.
23. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, John Wiley & Sons, Inc., New York. 1st ed.
24. Davidoff A.J., Rapp T., Onukwugha E., Zuckerman I.H., Hanna N., Pandya N., et al. Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care 2009, 47:1229-1236.
25. Zuckerman I.H., Rapp T., Onukwugha E., Davidoff A., Choti M.A., Gardner J., et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 2009, 57:1403-1410.
26. Davidoff A.J., Tang M., Seal B., Edelman M.J. Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2010, 28:2191-2197.
27. Davidoff A.J., Gardner J.F., Seal B., Edelman M.J. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:934-941.
28. Schneider M., Zuckerman I.H., Onukwugha E., Pandya N., Seal B., Gardner J., et al. Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysis. J Am Geriatr Soc 2011, 59:637-646.
29. Puts M.T.E., Hardt J., Monette J., Girre V., Springall E., Alibhai S.M.H. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 2012, 104:1133-1163.
30. Repetto L., Fratino L., Audisio R.A., Venturino A., Gianni W., Vercelli M., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 2002, 20:494-502.
31. Minino A.M., Heron M.P., Murphy S.L., Kochanek K.D. Deaths: final data for 2004. National Vital Statistics Reports 2007 2007, 55:1-119.
32. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch Surveillance, Epidemiology, and End Results (SEER)*Stat database http://seer.cancer.gov/seerstat/.
33. Ramsey S.D. How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. J Clin Oncol 2007, 25:175-179.